Kexin Health Industry Development

About Kexin Health Industry Development

Hunan Kexin Health Industry Development Co., Ltd., operating as Kexin Health, is a specialized hospital management group focusing on oncology. Established in 2014 by founder and Chairman Chen Lihong, who holds a Master's in Hospital Management from Peking University's medical department, the company has positioned itself as a significant player in China's private healthcare sector. Chen Lihong's background includes previous roles in specialized tumor hospitals, which provided the foundational experience for Kexin Health's strategic direction. The group operates a chain of tumor specialty hospitals with a geographical footprint covering cities like Changsha, Shaoyang, and Wuhan.

The company's business is centered on providing a comprehensive, full-lifecycle service chain for cancer patients, which encompasses prevention, screening, diagnosis, treatment, and rehabilitation. Kexin Health generates revenue through the operation of its network of owned and invested-in medical institutions. The service model is built upon a Multi-Disciplinary Team (MDT) consultation platform, ensuring that patients receive a holistic and scientifically-backed treatment plan. This approach is supported by investments in advanced international medical equipment and precision diagnostic technologies. A distinct feature is the "Yilifang" (Medical Cube) service, which provides a many-to-one patient care model, and the "Ten Fears, Ten Promises" responsibility mechanism, which aims to build patient trust by guaranteeing specific service standards, including a significant compensation for misdiagnosis.

Strategically, Kexin Health has pursued a multi-step growth plan focused on establishing flagship hospitals, expanding its national layout, and strengthening its brand. The company has successfully secured funding to fuel this expansion, including a notable RMB 240 million financing round in 2018 from investors such as Oriental Fortune Capital and Huagai Capital, aimed at constructing new facilities and upgrading technology. Recently, in July 2025, the company entered into an ecological fusion with Haier's Yingkang Yisheng platform, a strategic move to integrate its oncology resources with a broader healthcare ecosystem, filling a strategic gap in Central China and aiming to create a national benchmark in cancer care.